STOCK TITAN

Harmony Biosciences Holdings, Inc. - HRMY STOCK NEWS

Welcome to our dedicated page for Harmony Biosciences Holdings news (Ticker: HRMY), a resource for investors and traders seeking the latest updates and insights on Harmony Biosciences Holdings stock.

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) is a commercial-stage pharmaceutical company committed to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Established in 2017 and headquartered in Plymouth Meeting, PA, Harmony focuses on rare and orphan diseases, particularly those involving the central nervous system.

Harmony's flagship product is WAKIX® (pitolisant). This molecule is specifically designed to increase histamine signaling in the brain by binding to H3 receptors. It is used for the treatment of excessive daytime sleepiness (EDS) and cataplexy in adult patients with narcolepsy. WAKIX has been commercially available in the U.S. since Q4 2019 and continues to demonstrate strong market performance.

In recent developments, Harmony has initiated a global Phase 3 TEMPO study to evaluate pitolisant for treating EDS and behavioral symptoms in patients with Prader-Willi syndrome (PWS). The U.S. FDA granted Orphan Drug designation to pitolisant for this condition, further underscoring the potential of this therapy to address significant unmet medical needs.

The company's financial performance remains robust, with a 31% increase in net product revenue in Q4 2023 compared to the same period in 2022. Harmony’s strategic growth continues with key acquisitions, such as Epygenix Therapeutics, Inc., which expands its pipeline with promising treatments for rare forms of epilepsy like Dravet syndrome and Lennox-Gastaut syndrome.

Harmony recently announced the FDA's priority review for its supplemental New Drug Application (sNDA) for WAKIX for the treatment of EDS or cataplexy in pediatric patients aged six and older with narcolepsy. This decision highlights the pressing need for pediatric treatment options and demonstrates Harmony's commitment to broadening the clinical utility of its products.

Beyond narcolepsy, Harmony is exploring pitolisant's potential for other rare conditions, including Idiopathic Hypersomnia and Myotonic Dystrophy Type 1 (DM1). The company presented encouraging Phase 2 data showing pitolisant's efficacy in reducing EDS and fatigue in DM1 patients, paving the way for a pivotal Phase 3 study.

Harmony's collaborative efforts extend to partnerships with Bioprojet for the development of TPM-1116, an orexin-2 receptor agonist with potential applications in narcolepsy and other sleep/wake disorders. These initiatives align with the company's mission to deliver innovative treatments that improve the lives of patients living with rare neurological diseases.

For more information, please visit www.harmonybiosciences.com.

Rhea-AI Summary

On August 9, 2021, Harmony Biosciences (Nasdaq: HRMY) announced its acquisition of HBS-102, a potential first-in-class molecule for treating narcolepsy. The deal includes an upfront payment of $3.5 million, alongside potential milestone payments and royalties. HBS-102 targets melanin concentrating hormone (MCH) neurons, aiming to alleviate symptoms like cataplexy and REM sleep dysregulation. Harmony plans to submit an Investigational New Drug application to initiate a Phase 2 clinical trial. This acquisition marks Harmony's strategy to expand its product pipeline beyond its current offering, WAKIX®.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.63%
Tags
-
Rhea-AI Summary

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) will announce its second quarter 2021 financial results on August 10, 2021, at 8:00 a.m. ET. A conference call and webcast will follow at 8:30 a.m. ET. Investors can join the call by dialing (833) 614-1471 (domestic) or +1 (914) 987-7209 (international). A replay will be available within 24 hours, lasting until August 17, 2021. Harmony Biosciences focuses on developing therapies for rare neurological disorders and aims to address unmet medical needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.89%
Tags
-
Rhea-AI Summary

Harmony Biosciences Holdings (Nasdaq: HRMY) announced the initiation of a Phase 2 clinical trial to evaluate the safety and efficacy of pitolisant for excessive daytime sleepiness (EDS) and non-muscular symptoms in adult patients with type 1 myotonic dystrophy (DM1). Approximately 135 patients will receive low-dose, high-dose, or placebo pitolisant in a randomized study. The trial aims to address significant unmet medical needs as there are currently no approved treatments for DM1. Topline results are expected in the second half of 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.68%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
none
-
Rhea-AI Summary

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) announced a new analysis of WAKIX® (pitolisant) presented at SLEEP 2021, emphasizing its clinical effectiveness for excessive daytime sleepiness (EDS) and cataplexy in adults with narcolepsy. The analysis revealed a number needed to treat (NNT) of 5 for EDS at week 8 in the HARMONY 1 trial and an NNT of 3 for EDS and cataplexy at week 7 in the HARMONY CTP trial. Harmony's Chief Medical Officer highlighted the importance of these findings for treating patients with narcolepsy.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
none
-
Rhea-AI Summary

On June 9, 2021, Harmony Biosciences (Nasdaq: HRMY) announced that applications for its Patients at the Heart Grant Program are now open. This competitive grant initiative aims to support organizations addressing the challenges faced by individuals with sleep disorders and rare diseases experiencing excessive daytime sleepiness (EDS). The program, launched in 2019, has previously funded innovative patient-centric initiatives. Applications are accepted until August 20, 2021, and recipients will be announced in September 2021. For more details, visit Harmony's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1%
Tags
none
Rhea-AI Summary

Harmony Biosciences (Nasdaq: HRMY) announced on June 7, 2021 that two post-hoc analyses of WAKIX® (pitolisant) will be presented at the 35th Annual Meeting of the Associated Professional Sleep Societies from June 10-13. The first analysis evaluates the number needed to treat (NNT) and effect size for WAKIX in treating cataplexy and excessive daytime sleepiness in narcolepsy patients. The second focuses on cataplexy frequency data. WAKIX, FDA-approved since Q4 2019, targets excessive sleepiness and cataplexy, with significant data available from June 9 to November 30.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.15%
Tags
conferences
-
Rhea-AI Summary

Harmony Biosciences Holdings (Nasdaq: HRMY) announced participation in three upcoming investor conferences. President and CEO John Jacobs will host fireside chats at:

  • Jefferies Healthcare Conference on June 2, 2021, at 2:30 PM ET
  • Goldman Sachs 42nd Annual Global Healthcare Conference on June 10, 2021, at 3:50 PM ET
  • Raymond James Human Health Innovation Conference on June 21, 2021, at 3:20 PM ET

Live webcasts will be available on Harmony's investor page. The company focuses on innovative therapies for rare neurological disorders.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
conferences
-
Rhea-AI Summary

Harmony Biosciences announced the appointment of John C. Jacobs as a member of the Life Sciences Pennsylvania's Board of Directors, effective May 6, 2021. Under his leadership, Harmony has focused on innovative therapies for rare neurological disorders. Jacobs brings almost three decades of experience in the pharmaceutical sector, enhancing his ability to support local patient communities and advance the life sciences industry in Pennsylvania. His appointment underscores Harmony’s commitment to leadership within the sector and aims to bolster the company’s influence and initiatives in the region.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
management
Rhea-AI Summary

Harmony Biosciences Holdings, based in Plymouth Meeting, PA, announced a company update presentation at the Oppenheimer Rare and Orphan Disease Summit on May 21, 2021. President and CEO John C. Jacobs and Chief Medical Officer Dr. Jeffrey Dayno will host investor meetings during the event. The presentation will be accessible via a webcast on Harmony's investor page. The company focuses on developing therapies for rare neurological disorders with unmet medical needs.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.4%
Tags
conferences

FAQ

What is the current stock price of Harmony Biosciences Holdings (HRMY)?

The current stock price of Harmony Biosciences Holdings (HRMY) is $34.95 as of December 23, 2024.

What is the market cap of Harmony Biosciences Holdings (HRMY)?

The market cap of Harmony Biosciences Holdings (HRMY) is approximately 2.0B.

What is Harmony Biosciences' main product?

Harmony Biosciences’ main product is WAKIX® (pitolisant), used for treating excessive daytime sleepiness and cataplexy in adult patients with narcolepsy.

What recent studies has Harmony Biosciences initiated?

Harmony has initiated the global Phase 3 TEMPO study to assess pitolisant for treating excessive daytime sleepiness and behavioral symptoms in Prader-Willi syndrome patients.

What significant acquisitions has Harmony Biosciences made?

Harmony recently acquired Epygenix Therapeutics, adding a rare epilepsy franchise to its expanding pipeline, including treatments for Dravet syndrome and Lennox-Gastaut syndrome.

What recent FDA approvals or reviews has Harmony Biosciences received?

The FDA has granted Orphan Drug designation to pitolisant for Prader-Willi syndrome and priority review for its sNDA for WAKIX for treating EDS or cataplexy in pediatric patients.

What conditions is Harmony Biosciences exploring with pitolisant?

Besides narcolepsy, Harmony is exploring pitolisant for conditions like Idiopathic Hypersomnia and Myotonic Dystrophy Type 1 (DM1).

Where is Harmony Biosciences headquartered?

Harmony Biosciences is headquartered in Plymouth Meeting, PA.

What are some key financial highlights for Harmony Biosciences?

Harmony reported a 31% increase in net product revenue in Q4 2023 compared to the same period in 2022, driven by strong sales of WAKIX.

What partnerships is Harmony Biosciences involved in?

Harmony has a collaborative partnership with Bioprojet, focusing on developing TPM-1116, an orexin-2 receptor agonist for sleep/wake disorders.

How can I get more information about Harmony Biosciences?

For more information, please visit their website at www.harmonybiosciences.com.

What is the mission of Harmony Biosciences?

Harmony Biosciences aims to develop and deliver innovative treatments for rare neurological diseases with a focus on improving patient lives through empathy and innovation.

Harmony Biosciences Holdings, Inc.

Nasdaq:HRMY

HRMY Rankings

HRMY Stock Data

1.95B
38.55M
11.62%
93.1%
10.17%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
PLYMOUTH MEETING